Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

ORIGINAL ARTICLE

Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: A prospective randomized trial in Algeria

Aribi Mourad, Mesli Naima, Remla Nesrine, Sari Badr-Eddine, Taleb Abdesselam, Touhami Hadj, Bekadja Mohamed-Amine, Zouaoui-Benhadji Zahia, Bouzid Kamel, Meguenni Kaoual

Year : 2010| Volume: 6| Issue : 1 | Page no: 41-46

   This article has been cited by
 
1 Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL
Lamiss Mohamed Abd el Aziz
Medical Oncology. 2014; 31(11)
[Pubmed]  [Google Scholar] [DOI]
2 Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
David J. Straus,Paul A. Hamlin,Matthew J. Matasar,Maria Lia Palomba,Pamela R. Drullinsky,Andrew D. Zelenetz,John F. Gerecitano,Ariela Noy,Audrey M. Hamilton,Rebecca Elstrom,Brett Wegner,Katy Wortman,David Cella
British Journal of Haematology. 2014; : n/a
[Pubmed]  [Google Scholar] [DOI]
3 Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review
Ann Colosia,Annete Njue,Peter C. Trask,Robert Olivares,Shahnaz Khan,Adeline Abbe,Rachel Police,Jianmin Wang,Rodrigo Ruiz-Soto,James A. Kaye,Farrukh Awan
Clinical Lymphoma Myeloma and Leukemia. 2014;
[Pubmed]  [Google Scholar] [DOI]
4 GDP regimen as salvage treatment for relapsed refractory non-Hodgkinæ s lymphoma
Zhao, J. and Feng, K.-C. and Zhao, Z.-Q. and Su, L.-P. and Wang, J. and Ma, L. and He, J.-X. and Wang, L.-Y. and Li, X. and Wang, Y.-L. and Han, W.-E. and Zheng, Y.-P.
Journal of Leukemia and Lymphoma. 2012; 21(8): 472-474
[Pubmed]  [Google Scholar]
5 Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines
Benigno C. Valdez,David Murray,Yago Nieto,Yang Li,Guiyun Wang,Richard E. Champlin,Borje S. Andersson
Leukemia & Lymphoma. 2012; 53(5): 973
[Pubmed]  [Google Scholar] [DOI]
6 Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines
Valdez, B.C., Murray, D., Nieto, Y., Li, Y., Wang, G., Champlin, R.E., Andersson, B.S.
Leukemia and Lymphoma. 2012; 53(5): 973-981
[Pubmed]  [Google Scholar]

 

Read this article